Annual Congress: Hematologic Malignancies
The NCCN 2024 Annual Congress: Hematologic Malignancies™ was held on September 20 – Saturday, September 21, 2024, in New York and virtually.
Save the date! The NCCN 2025 Annual Congress: Hematologic Malignancies™ will take place in Fall 2025 in San Diego, California.
Continuing Education
Congress attendees will have the opportunity to view sessions on-demand in the Virtual Event Platform through December 2024. Recorded sessions will be available in the NCCN Continuing Education Portal, education.nccn.org, later this year.
Chaired by Andrew D. Zelenetz, MD, PhD, from Memorial Sloan Kettering Cancer Center, this program featured presentations and interactive discussions highlighting the treatment options and supportive care for a variety of hematologic malignancies. This program was approved for AMA PRA Category 1 Credit™ and ABIM, ABPath, and ABMS MOC for physicians and is certified for credit for PAs, nurses, pharmacists, and other oncology professionals.
Topics and disease covered:
- Acute Lymphocytic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Amyloidosis
- Bispecific Antibodies
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- CAR T-Cell Therapies
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Chronic Myeloid Leukemia
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndromes (MDS)
- Myelofibrosis
- Primary CNS Lymphoma
For CE program supporter opportunities, contact Lisa Perfidio, Senior Manager, CE Supporter Outreach.
This activity is supported by educational grants from:
- AstraZeneca
- Geron
- Ipsen Biopharmaceuticals, Inc.
- Lilly
- Menarini-Stemline
- Novartis
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Sanofi
- Taiho Oncology, Inc.
This educational activity is supported by independent medical educational grants from:
- AbbVie
- ADC Therapeutics
- GSK
Supported by independent educational grants from:
- Daiichi Sankyo
- Incyte Corporation
- Rigel Pharmaceuticals, Inc.
Supported by a grant from:
- Pfizer Inc.
Patient Advocacy Pavilion Sponsors
Emerald
AstraZeneca
BeiGene
Coherus
Eisai
Incyte Corporation
Johnson & Johnson
Topaz
Important Alert About Fraudulent Sites
Information about this Congress may appear on fraudulent websites that appear to offer registration, exhibit space, and hotel rooms at discounted rates. These companies are in no way affiliated with NCCN. Please do not book any registrations or reservations through these sites, and register only through NCCN. If you have any questions or concerns, contact conferences@nccn.org.